A homogeneous substrate-labeled fluorescent immunoassay has been applied to the measurement of phenytom concentrations in human serum. We coupled a fiuorogenic enzyme substrate, galactosyl-umbelliferone, covalently to a derivative of phenytoin. Under assay conditions, this drug-substrate conjugate was nonfluorescent but became fluorescent upon hydrolysis catalyzed by bacterial f3-galactosidase. When antibody to phenytoin is bound to the drug-substrate conjugate, it is inactive as an enzyme substrate. Addition of phenytoin to Competitivebinding reactions relieves the inactivation, and the resulting fluorescence is proportional to the phenytoin concentration. We validated the fluorescent immunoassay by comparing values for phenytoin obtained with this technique to those obtained by gas chromatography and by enzyme immunoassay (EMIT#{174}). All three methods correlated well.
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The major metabolite of phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin, and other drugs at concentrations expected in serum had no effect on the assay. The fluorescent immunoassay is rapid and simple to perform and requires only 2 L of serum sample per test. (1). The major assay methods for PHT are EMIT (2), gas chromatography (3), "high-pressure" liquid chromatography (4), and radioimmunoassay
(5).
We have developed several nonradioisotopic immunoassay PHT is labeled with a fluorogenic enzyme substrate, /3-galactosyl-umbelliferone (f3G-U). Under assay conditions, the f3G-U-PHT conjugate is nonfluorescent; but when treated with an enzyme, a fluorescent product is produced. When the /3G-U-PHT is bound by a specific antibody (Ab), a complex is formed that prevents interaction of the bound f3G-U-PHT with the enzyme. Addition of PHT from the serum samples results in a competition with the 3G-U-PHT for binding sites on the antibody, thus reducing the amount of antibody-bound /IG-U-PHT. Hence the amount of /3G-U-PHT available for reaction with the enzyme is proportional to the concentration of PHT being assayed. This fluorescent immunoassay does not require separation steps because the /3G-U-PHT bound to antibody does not react with enzyme. In addition, a relatively small volume of serum is needed and the fluorescent assay is rapid and simple. silica gel 60 with carbon tetrachloride/acetone, 9/1 (by vol) as solvent. Twenty-milliliter fractions were collected, and fractions 276 to 803 were combined. The final step involved the reaction of (III) with 7-fl-galactosylcoumarin-3-carboxylic acid (IV), which had been prepared as described by Burd et al. (9). We combined 216 mg of ethyl chloroformate with 808 mg of (IV) in 20 mL of dimethylformamide at 0 #{176}C. After stirring for 1 h at this temperature to allow the formation of the mixed anhydride of (IV), we added 638 mg of (III), 244 mg of 4-dimethylaminopyridine, and 5 mL of dry pyridine. The reaction was allowed to proceed overnight at 0 #{176}C. Then the solvent was removed Correlation coefficient = 0.966.
Materials and Methods

Instruments
1.3mg of the immunogen in 1 mL of 8.5 g/L saline was emulsified with an equal volume of complete Freund's adjuvant and injected subcutaneously into New Zealand white rabbits Booster injections were administered intravenously with 1.1 mg of the immunogen at 21 and 23 days after the initial injection. The animals were bled 10 days after the last injection.
Subsequently, the booster was repeated every 30 days and blood was collected 10 days after each booster.
Results
Absorbance and Fluorescence Spectra of fG-U-PHT
Analysis of the absorbance spectrum of /3G-U-PHT in Bicine buffer, 50 mmol/L, pH 8.2, showed a peak at 343 nm.
After hydrolysis, catalyzed by bacterial /3-galactoeidase, a new maximum appeared at 403 nm while the one at 343 nm decreased. The absorbance maximum of the hydrolyzed (IG-U-PHT (i.e., U-PHT) was 1.6 times that of the untreated conjugate.
Hydrolysis of /3G-U-PHT by fi-galactosidase shifted the fluorescence-excitation maximum from 355 to 410 nm, and the emission maximum was changed from 405 nm to 453 nm. 
Enzymatic Hydrolysis of 13G-U-PHT
Kuby and Lardy (13) found that the maximum rate of o-
hydrolysis by E. coli /3-galactosidase is in the pH range of 7.2 to 7.4. Under the conditions of our experiments, in which /IG-U-PHT is the substrate, the enzyme has an optimum activity between pH 6 and 8. Because the fluorescent intensity of hydrolyzed (IG-U--PHT increases up to pH 8.0 and remains nearly constant to at least pH 10, we conducted further investigations at pH 8.2 to maximize fluorescence intensity and to obtain adequate fi-galactosidase activity. The enzyme activity at pH 8.2 is 0.67 times the activity at pH 7.
Various amounts of /3G-U-PHT were added to a series of 
Antibody-Binding Reactions
The ability of /3G-U-PHT to serve as an enzymatic substrate in the presence of antiserum to PHT was examined. Various volumes of antiserum or normal rabbit serum were added to 3.0 mL of buffer containing, per liter, 50 mmol of Bicine, 15.4 mmol of sodium azide, and 40 units of fi-galactosidase. (IG-U-PHT was added to give a final concentration of 33 nmol/L, and the reactions were allowed to proceed for 20 mm at room temperature.
Fluorescence was measured at the end of the incubation period. The fluorescence decreased in cuvets containing antiserum; it was unaffected in cuvets containing normal rabbit serum (Figure 2) .
The IIG-U-PHT was used to titer antiserum from several bleedings of one rabbit. The results in Figure 2 show that the titer reached a maximum by the third bleeding and was sustained through the seventh bleeding. A Scatchard plot for the 
Competitive-Binding Reactions
The effect of incubation time with fi-galactosidase on the standard curve obtained from competitive-binding reactions was examined. Competitive-binding reactions were conducted by adding various levels of PHT to 3.1-mL reaction mixtures that contained 0.04 unit of fi-galactosidase and 5 1zL of the antiserum. (This amount of antiserum inhibited the production of fluorescence to 10% of that observed in the absence of antibody.) One hundred-microliter aliquots of $G-U-PHT (1.05 tmol/L) were added sequentially to each mixture at 30-s intervals and mixed. The reaction mixtures were allowed to stand at room temperature for various lengths of time. The fluorescence intensities were measured at 30-s intervals in the same sequence as the flG-U-PHT was added.
As the amount of PHT increased, the fluorescence increased because less fIG-U-PHT was bound to antibody ( Figure 3 ). To establish the validity of the SLFIA, we determined PHT amounts in clinical sera by SLFIA, gas chromatography, and EMIT methods and compared the results. The correlation coefficient between the SLFIA and gas-chromatographic methods ( were compared with those found by means of gas chromatography ( 
S.E.=115
S. give an error of 10% with this standard. This is more than 15 times the amount (2 mg/L) normally found in patients' serum (15) .
Discussion
In the SLFIA for PHT, we use a single-point reading of fluorescence, which differs from the rate assay we used in the fluorescent immunoassay for gentamicin (9). This modification simplifies the assay procedure and data processing. In the present assay there is a 20-mm incubation period between adding the fJG-U-PHT and reading the fluorescence. If the 3G-U-PHT is added to each cuvet at 30-s intervals, a maximum of 40 assays can be performed within the 20-mm period. However, as the results in Figure 3 indicate, an acceptable standard curve can be obtained anytime between 5 mm and 7 h after the addition of /3G-U-PHT. Hence, the operator has the flexibility of varying the incubation time according to the number of samples being assayed, as long as all the cuvets are incubated for the same period. The range of SLFIA is between 0 and 30 mg/L, which should cover the PHT concentrations most commonly encountered in clinical serum specimens. Sera with PHT concentrations greater than 30 mg/L are diluted 100-fold instead of 50-fold and assayed by the usual procedure.
The concentration values obtained for these 100-fold dilution are then multiplied by 2 to give the PHT values for these sera (Table 1) . When various amounts of PHT were added to serum, the recoveries measured with SLFIA were generally greater than 100% (Table 3 ). This positive bias appears to be due to experimental error, because no bias was evident in the dilution studies (Table 4) or the correlation studies (Figures 4 and   5 ).
PHT amounts determined with SLFIA correlate well with results from both EMIT and gas chromatographic methods.
A small serum sample volume, 100 tL of 50-fold diluted serum or 2 zL of undiluted serum, is used for SLFIA, and no extraction procedures are required. Because the antibody-bound and the free 13G-U-PHT need not be separated, the assay is rapid and simple to perform.
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